Stockscreener 앱 받기
19.04
2.64%
0.49
시간 외 거래:
18.50
-0.54
-2.84%
전일 마감가:
$18.55
열려 있는:
$18.67
하루 거래량:
1.90M
Relative Volume:
1.15
시가총액:
$1.69B
수익:
$217.42M
순이익/손실:
$-243.25M
주가수익비율:
-6.8117
EPS:
-2.7952
순현금흐름:
$-278.35M
1주 성능:
+8.30%
1개월 성능:
-5.88%
6개월 성능:
-6.53%
1년 성능:
+97.51%
1일 변동 폭
$18.64
$19.29
1주일 범위
$17.31
$19.29
52주 변동 폭
$8.585
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
19.04 | 1.64B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Syndax Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Syndax Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Eventide Asset Management LLC Has $26.01 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial DataWhat's Changed - Yahoo Finance
Voss Capital LP Buys Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Rhenman & Partners Asset Management AB Sells 87,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options - Stock Titan
SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
SNDX Stock Price, Quote & Chart - ChartMill
[144] Syndax Pharmaceuticals Inc SEC Filing - Stock Titan
Syndax showcases revuforj (revumenib) data at EHA 2026 - grafa.com
Syndax (SNDX) Reveals Encouraging Results from SAVE Trial for AM - GuruFocus
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX) - Seeking Alpha
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - The Manila Times
Leukemia drug revumenib shows up to 97% remission in EHA 2026 data - Stock Titan
Syndax Pharmaceuticals Announces Publication of Save Data on Revuforj in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML - marketscreener.com
SNDX6417984 Bond Coupon Analysis — Rate & Payments - TradingView
Syndax Pharmaceuticals (NASDAQ: SNDX) issues $250M 2.25% convertible notes due 2031 - Stock Titan
Syndax (NASDAQ: SNDX) investors back 2026 equity plan and new ESPP - Stock Titan
Syndax Pharmaceuticals, Inc. Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Inc Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNDX) - MarketBeat
SNDX6417984 Bond Analysis — Key Metrics - TradingView
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 02 - marketscreener.com
SNDX: Revuforj's clinical success and expanding pipeline drive growth, with new capital fueling future innovation - TradingView
Syndax Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
SNDX6417984 Bond Price and Chart — FINRA:SNDX6417984 - TradingView
Price-Driven Insight from (SNDX) for Rule-Based Strategy - Stock Traders Daily
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Recent Share Price Weakness - Sahm
Syndax Pharmaceuticals prices $250M senior convertible notes - MSN
Syndax Pharmaceuticals prices $250 million convertible notes By Investing.com - Investing.com Australia
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax (SNDX) Launches $250M Convertible Senior Note Offering - GuruFocus
Syndax Pharmaceuticals (SNDX) Faces Selling Pressure, Testing Near-Term Support LevelsLiquidity Order Flow - newsline.com
Syndax Pharmaceuticals prices $250 million convertible notes - Investing.com UK
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Syndax Pharmaceuticals Prices $250 Million Convertible Senior Notes - TipRanks
Syndax Prices $250 Million 2.25% Convertible Notes Due 2031 in Private Placement - TradingView
Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031 - Stock Titan
Syndax Pharmaceuticals Announces $250 Million Private Placement of Convertible Senior Notes - Quiver Quantitative
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes - The Manila Times
Syndax lines up $250M in 2.25% debt swappable into its stock - Stock Titan
H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating on ASCO data - Investing.com Canada
Stifel reiterates Syndax Pharmaceuticals stock rating on ASCO data By Investing.com - Investing.com Canada
Syndax (SNDX) CFO sells 1,177 shares to cover RSU tax withholding - Stock Titan
Syndax Pharmaceuticals (SNDX) CEO sells shares to cover tax obligations - Stock Titan
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data - The Manila Times
Small leukemia study finds 90% 2-year survival with revumenib after transplant - Stock Titan
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 - The Manila Times
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Syndax Pharmaceuticals Inc 주식 (SNDX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Option Exercise |
13.82 |
22,515 |
311,157 |
95,165 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Sale |
18.00 |
34,280 |
617,040 |
60,885 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 12 '26 |
Sale |
18.14 |
31,235 |
566,603 |
60,885 |
2.60%
0.94%
자본화:
|
볼륨(24시간):